Rosana Kapeller explains how Rome is looking at areas of the genome that do not encode for traditional proteins as the basis of disease.

Mike Nally describes Generate's near term programs how he sees computational advances changing where the field is headed over the long term.

Brian Skorney discusses this week’s data from Neurocrine Biosciences and Crinetics, and comments on Amgen, Regeneron, and Arbutus.

Stephen Hoge explains how Moderna is partnering on programs that include CAR-T, TCRs, bi-specifics, and in-vivo editing programs.

Stéphane Bancel comments on the fall covid vaccine rollout, pushing into earlier stages of cancer, and rare diseases.

Dennis Purcell talks about the biotech downturn, what areas of science interest him going forward, and memories of Hambrecht & Quist.

Simon Read discusses the use cases for radiopharmaceuticals and why Mariana has chosen small cell lung cancer for its first indication.

Discussing rare disease, psychiatric research, infectious disease, and cancer with experts from the Broad Institute.

Brent Saunders describes a recent deal Bausch + Lomb has made in dry eye disease and his goal to push further into retinal diseases as well.

Dr. Frost describes the elements needed for a city to spark biotech innovation and the progress that Miami has been making.

The Nucleate Florida team reflects on an evening of networking and discussions on the past, present, and future of Florida biotech.

Rachel Haurwitz describes recent data and the durability profile of Caribou’s allo CAR-T as the company plans to discuss a pivotal with FDA.

Jake Becraft describes emerging new techniques in using mRNA and gives BiotechTV a tour of Strand’s Fenway HQ to show us the R&D process.

Evan Seigerman gives his take on biotech and the CMS list, Lilly, Amgen, Skyscraper-01, Structure Therapeutics, Disc Medicine and Replimune.

Chris Heery describes the process relating to bridging therapy that enabled a partial clinical hold to lift.

Fabian Gerlinghaus walks us through how the Cell Shuttle is designed to improve the time and cost of manufacturing cell therapies.

Dr. Levine talks about emerging technology trends that might improve CAR-T therapies on the six-year anniversary of the first approved CAR-T

Seth Ettenberg describes safety, imaging, and efficacy takeaways from the 12-patient study.

Tessera’s CEO explains gene writing and then we take a tour to learn about high-throughput testing, RNA purification, and LNP encapsulation.

BiotechTV toured Bayer’s Kendall Square location to see how it collaborates with the local biotech ecosystem.